# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN
- Date: 2026-09-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dale Rasmussen, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Mr. Knievel is a 57-year-old retired stunt performer with compensated cirrhosis from hepatitis C, cured by 12 weeks of sofosbuvir-velpatasvir, who comes for his yearly preventive visit five weeks after the test that confirmed cure. He has had no alcohol since the start of treatment. He takes carvedilol 12.5 mg daily without dizziness, and had his zoledronic acid infusion in June without a reaction. His pain is about 4 of 10; he goes to the pool twice a week and walks 30 minutes on flat ground most days. He has had no falls since starting physical therapy. His glucose sensor shows no low readings. He has had no abdominal swelling, black stools, confusion or yellowing of the eyes. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 57 |
| Liver | Hepatitis C cured; compensated cirrhosis; carvedilol; next surveillance ultrasound in February |
| Alcohol | None since the start of treatment |
| Mood | PHQ-2 0 |

## Health risk assessment

Completed by the patient on the clinic's online form before the visit and reviewed with him by Dr. Rasmussen. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good; better than in years |
| Psychosocial | Busy with appearances and travel; good support from family and friends |
| Substance use | No alcohol since February; never smoked; no drug use |
| Physical activity | Pool exercise twice a week; walks 30 minutes most days; some golf |
| Nutrition | Three meals and a late-evening snack; protein at each meal; less salt |
| Sleep | Six to seven hours; wakes with hip pain once a night |
| Falls and home safety | No falls since physical therapy; grab bars and a shower chair; cane on long walks |
| Driving | Drives in daytime; always wears a seat belt |
| Activities of daily living | Independent in all |
| Smoke alarms and firearms | Smoke alarms tested; no firearms at home |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; no fever or weight loss |
| Eyes | Negative | No vision change; retinal examination in June normal |
| Ears, nose, mouth, and throat | Negative | No hearing change or nosebleeds |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting blood |
| Genitourinary | Negative | No urinary hesitancy, frequency or blood in the urine |
| Musculoskeletal | Positive | Hip, knee and back pain, about 4 of 10 |
| Integumentary | Negative | No yellowing, itching or new skin lesions |
| Neurological | Negative | No confusion, sleep reversal or tremor |
| Endocrine | Negative | No low glucose readings |
| Psychiatric | Negative | Mood good; PHQ-2 0 |

12 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day **S**
- Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day **S**
- Carvedilol 12.5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily **S**
- Zoledronic acid 5 mg in 100 mL, intravenous infusion over at least 15 minutes, once a year **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/74 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 82.4 kg; BMI 26 kg/m². All vital signs are synthetic.

Total cholesterol: 148 mg/dL; LDL cholesterol: 68 mg/dL; HDL cholesterol: 42 mg/dL; Triglycerides: 140 mg/dL; PSA: 1.3 ng/mL; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Total cholesterol: 186 mg/dL at baseline, 148 mg/dL at this visit **S**
- LDL cholesterol: 112 mg/dL (high) at baseline, 68 mg/dL at this visit **S**
- HDL cholesterol: 38 mg/dL (low) at baseline, 42 mg/dL at this visit **S**
- Triglycerides: 178 mg/dL (high) at baseline, 140 mg/dL at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Immunizations given today

- Influenza vaccine, inactivated, trivalent, preservative free, this season **S**
- Pneumococcal conjugate vaccine PCV20 **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 82.4 kg; blood pressure 122/74; pulse 62 |
| Eyes | No scleral icterus |
| Skin | A few spider angiomas on the chest, fewer than before; palmar erythema; no jaundice |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Spleen tip palpable; no ascites or tenderness |
| Musculoskeletal | Reduced hip rotation on both sides; old fracture deformities of the forearms; knees with crepitus |
| Feet | Monofilament sensation intact; pulses present; no ulcers |
| Neurological | No asterixis; gait slow but steady; Timed Up and Go 11 seconds |
| Psychiatric | Cheerful and blunt |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. Colorectal cancer screening is due at 57 and he has never been screened: colonoscopy ordered; carvedilol continues, and platelets of 134 do not stand in the way. Prostate cancer screening was discussed, including the chance of false positives and overtreatment, and he chose a PSA test: 1.3 ng/mL. Lipids on atorvastatin: LDL 68 mg/dL. Influenza, PCV20, the first recombinant zoster dose and Tdap given today; hepatitis A and B vaccine series are complete. **S**
   - Colonoscopy in the next two months.
   - Second zoster dose in two to six months.
   - COVID-19 vaccine this season.
   - Dental and eye examinations yearly.
   - Next preventive visit in one year.
2. **Compensated cirrhosis after hepatitis C cure** (K74.69). No sign of decompensation; cirrhosis remains after cure, so liver cancer surveillance continues. **S**
   - Ultrasound with alpha-fetoprotein in February.
   - Continue carvedilol 12.5 mg daily.
   - No alcohol.
3. **Type 2 diabetes** (E11.65). Glucose management indicator 6.8% a month ago; no hypoglycemia; foot examination normal. **S**
   - Continue metformin and the glucose sensor.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 122/74 mmHg on carvedilol |
| Depression screening | Completed today | PHQ-2 score 0; PHQ-9 3 a month ago |
| Unhealthy alcohol use screening and counseling | Completed today | No alcohol since February; abstinence reinforced |
| Tobacco use | Completed today | Never |
| Colorectal cancer screening | Ordered | Never screened; colonoscopy ordered |
| Prostate cancer screening | Completed today | Shared decision; he chose testing; PSA 1.3 ng/mL |
| Lung cancer screening | Not indicated | Never smoked |
| Diabetes and lipid care | Completed today | Glucose management indicator 6.8%; LDL 68 mg/dL on atorvastatin; urine albumin normal in January |
| Hepatitis C, hepatitis B and HIV screening | Up to date | Hepatitis C treated and cured; hepatitis B and HIV negative in January |
| Liver cancer surveillance | Up to date | Ultrasound and alpha-fetoprotein in August; next in February |
| Osteoporosis | Up to date | Zoledronic acid in June; bone density again in two years |
| Fall risk | Completed today | No falls since physical therapy; Timed Up and Go 11 seconds |
| Influenza, pneumococcal, zoster and Tdap vaccines | Completed today | Given today |
| Hepatitis A and B vaccines | Up to date | Both two-dose series complete |
| COVID-19 vaccine, this season | Due | At his pharmacy this autumn |
| Dental and eye examinations | Up to date | Dental review before zoledronic acid in May; retinal examination in June |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He wants full treatment, including a liver transplant evaluation if his liver ever fails, and wants to be told plainly how he is doing. He named a health care agent, recorded in the confidential part of the chart and not named here. He chose not to complete other treatment preferences today. To be revisited yearly or if his health changes. **S**

## Guideline basis

- Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023), American Association for the Study of Liver Diseases
- American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026), American Diabetes Association
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force
- Prostate Cancer: Screening (2018), U.S. Preventive Services Task Force

## Follow-up

- Colonoscopy in the next two months. Liver ultrasound with alpha-fetoprotein in February. Hepatology review with liver stiffness a year after cure. Second zoster dose in two to six months. Next preventive visit in one year. **S**

